Healthy lifestyle consciousness index
The HLCI included five items. "Diet," "exercise," "body weight," and "sleep” are the major components of lifestyle; thus, the HLCI consisted five questionnaires including these four items and a questionnaire on general health awareness. The following were the five questionnaires scaled from 0 to 9: 1) Do you live with consciousness of healthy lifestyle and habits? 2) Do you manage diets with consciousness of cancer in your daily life? 3) Do you exercise with consciousness of cancer in your daily life? 4) Do you manage your body weight with consciousness of cancer in daily life? 5) Do you manage to sleep with consciousness of cancer in your daily life? HLCI was calculated as the sum of the scores of the questionnaires (Table 1). HLCI was designed to evaluate the consciousness of patients regarding healthy lifestyle and not healthy lifestyle behaviors.
Table 1
Healthy lifestyle-consciousness index (HLCI)
Questions | Index scores |
Do you live with consciousness of a healthy lifestyle and habits? | 0 to 9 |
Do you manage diets with consciousness of cancer in your daily life? | 0 to 9 |
Do you exercise with consciousness of cancer in your daily life? | 0 to 9 |
Do you manage your body weight with consciousness of cancer in daily life? | 0 to 9 |
Do you manage to sleep with consciousness of cancer in your daily life? | 0 to 9 |
Healthy lifestyle-consciousness index (HLCI) = the sum all questionnaire scores | 0 to 45 |
Background of patients
In total, 108 patients were included in the present study. Patient backgrounds are summarized in Table 2. The mean age of the 108 patients was 55.8 years (standard deviation [SD]: ± 12.2 years). Thirty-three patients (30.6%) had uterine cervical cancer, 39 (36.1%) had uterine corpus cancer, 34 (31.5%) had ovarian, fallopian tube, and peritoneal cancer, one (0.9%) had double cancer including uterine corpus cancer and ovarian cancer, and one (0.9%) had vulvar cancer. Ninety patients (83.3%) were diagnosed with primary disease, whereas 18 patients (16.7%) had recurrent disease. Fifty-four patients (50.0%) were diagnosed with stage I, 17 (15.7%) with stage II, 24 (22.2%) with stage III, and 13 (12.0%) with stage IV disease. Thirty-one patients (28.7%) were before treatment, 45 patients (41.7%) were under treatment, and 32 patients (29.6%) were under follow-up after treatment.
Table 2
Backgrounds of study participants
Factors | Variable | Number of the cases | % |
Age | Thirties | 8 | 7.4 |
Forties | 29 | 26.9 |
Fifties | 30 | 27.8 |
Sixties | 23 | 21.3 |
More than seventy | 18 | 16.7 |
Types | Uterine cervical cancer | 33 | 30.6 |
Uterine corpus cancer | 39 | 36.1 |
Ovarian, fallopian tube, and peritoneal cancers | 34 | 31.5 |
Double cancer | 1 | 0.9 |
Vulvar cancer | 1 | 0.9 |
Primary or recurrence | Primary | 90 | 83.3 |
Recurrence | 18 | 16.7 |
Stage | I | 54 | 50.0 |
II | 17 | 15.7 |
III | 24 | 22.2 |
IV | 13 | 12.0 |
Treatment status | Before treatment | 31 | 28.7 |
During treatment | 45 | 41.7 |
After treatment | 32 | 29.6 |
Structural validity of the HLCI
The exploratory factor analysis showed that HLCI in gynecological cancer patients exhibited a unidimensional structure based on the pattern of eigenvalues; it decreased remarkably with the second factor and later factors (Fig. 1-a). This implies that healthy lifestyle consciousness among gynecological cancer patients comprises a single concept of “healthy lifestyles.” Therefore, the total additional score of each questionnaire on the healthy lifestyle index in cancer patients was used in this study. The HLCI ranged from 0 to 45. The mean HLCI was 25.1 (SD: ± 9.3); the minimum and maximum HLCI in this study were 5 and 44, respectively. The distribution of HLCI score is shown in Fig. 1-b, indicating no remarkable floor and ceiling effects in patients of the present study (Fig. 1-b).
Reliability of HLCI
The Cronbach's alpha for all five questionnaires was 0.88, indicating high reliability.
Criterion-based validity: relationship between HLCI and clinical status
To evaluate the criterion-related validity of HLCI, gynecological cancer patients were categorized using tertiles (T1, low tertile, n = 39; T2, middle tertile, n = 33; T3, high tertile, n = 36) based on the scores of HLCI and compared using clinical backgrounds. The proportion of patients with recurrent disease in T3 was higher than that in T2 and T1 (22.2%, 15.1%, and 12.8%, respectively; Fig. 2-a). Similarly, the proportion of patients with stage III and stage IV disease in T3 was higher than that in T2 and T1 (44.4%, 33.3%, and 25.6%, respectively; Fig. 2-b). Considering patients during treatment, the proportion was the highest in T3 followed by T2 and T1 (55.6%, 39.4%, and 30.7%, respectively; Fig. 2-c).
Concurrent validity: relationship between HLCI and other QOL scales
To evaluate the concurrent validity of HLCI, three groups categorized using tertiles based on the HLCI scores in gynecological cancer patients were compared in QOL scales comprising global health status of EORTC QLQ-C30 and PHQ9 (n = 25). The global health status, a measure of the overall QOL, was highest in T3 (mean value = 79.2) compared to T2 and T1 (mean values = 54.2 and 48.1, respectively; Fig. 3-a). The global health status and HLCI were significantly correlated (Spearman r = 0.43, p = 0.03). The PHQ9 score, a measure of depressive symptoms, was highest in T1 (mean value = 6.3) compared to T2 and T3 (mean values = 4.4 and 2.1, respectively; Fig. 3-b). The PHQ9 and HLCI were significantly correlated (Spearman r=-0.45, p = 0.04)